As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration.
00:00 - Introduction 01:41 - AI Hype to Proof 04:52 - Where AI Adds Value 13:30 - AI for Clinical Trials 17:01 - Agentic AI in R&D 25:34 - Out-of-Domain Prediction 28:24 - Future of Techbio 31:13 - Precompetitive Consortia 35:24 - CEO Leadership and Catalysts
Podden och tillhörande omslagsbild på den här sidan tillhör
BioCentury. Innehållet i podden är skapat av BioCentury och inte av,
eller tillsammans med, Poddtoppen.
